Stifel initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $27 price target The firm says its bullish thesis is based on enthusiasm for LB-102, which it thinks can become a blockbuster antipsychotic for the treatment of schizophrenia and mood disorders. It views schizophrenia as “mostly derisked” following the “strong” Phase 2 data.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX: